Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior Treatment
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
Omega DUROS® is an implantable drug delivery system designed to deliver omega interferon
subcutaneously at a constant rate for 90 days.
This study is being performed to evaluate the safety and antiviral effects of omega
interferon delivered by the Omega DUROS® device in combination with ribavirin in subjects
with chronic Hepatitis C genotype 1.